Physician profile
Guy El Helou
NPI 1255783528
$2,148.03
in general payments reported to CMS, 2019-2025
13 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $108 · 2024: $549 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Consulting Fee: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.03 |
| Consulting Fee | $630.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $737.45 | 2024-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $275.49 | 2024-2025 | Zevtera, Xerava |
| Melinta Therapeutics, LLC | $203.55 | 2024-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Abbvie INC. | $151.84 | 2025 | |
| Paratek Pharmaceuticals, INC. | $124.70 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $122.48 | 2024-2025 | Zerbaxa, Prevymis, Dificid |
| Astellas Pharma US INC | $116.42 | 2024-2025 | Cresemba |
| Takeda Pharmaceuticals U.S.A., INC. | $108.38 | 2023 | Livtencity |
| Aimmune Therapeutics, INC. | $88.39 | 2024-2025 | Vowst |
| Ferring Pharmaceuticals INC. | $87.08 | 2024-2025 | Rebyota |
| Insmed, INC. | $83.59 | 2024-2025 | Arikayce |
| Tetraphase Pharmaceuticals, INC. | $34.86 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $13.80 | 2024 | Vibativ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy El Helou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.